All sponsors

Jiangsu vcare pharmaceutical technology co., LTD

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-35
RECRUITING8
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO0%

Delay Index: of 5 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Jiangsu vcare pharmaceutical technology co., LTD on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
VC004 Capsules
NCT06658353
P3RecruitingLocally Advanced Solid Tumor542026-12-30
Vicagrel
NCT06577519
P3RecruitingAcute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)10002026-12-30
VC005 group
NCT07598383
P2RecruitingAtopic Dermatitis1202027-02-22
VC005 tablets
NCT07828639
P1/2Not yet recruitingNon-Segmental Vitiligo102027-05-30
VC005 tablets
NCT07172347
P2RecruitingNon-segmental Vitiligo1202027-08-30
VC005 tablets
NCT07172360
P3RecruitingActive Ankylosing Spondylitis4202027-08-30
VC005 low dose group
NCT06723080
P3RecruitingModerate to Severe Atopic Dermatitis4802027-08-30
VC005
NCT07592585
P3RecruitingAtopic Dermatitis3602028-05-30
Drug: VC005 tablets
NCT07749716
P2RecruitingAlopecia Areata1202028-12-30